Food And Drug Administration
-
Neil Osheroff: Winning the War on Bacteria
Crucial research by Neil Osheroff and his lab leads to approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, will be available starting later this year, potentially bringing relief to thousands of women who struggle with uncomplicated urinary tract infections. Read MoreApr 28, 2025
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023